HUYA Bioscience International sources pharmaceutical innovation originating in China for global development in international markets. With eight offices staffed with dedicated scientists throughout China, the Company has amassed the largest compound portfolio covering all major therapeutic areas. HUYA has emerged as the partner-of-choice for maximizing the value of biopharmaceutical innovation from China by developing both early and late stage drug candidates in concert with our partners primarily in oncology and cardiovascular disease (Please see Pipeline: www.huyabio.com/pipeline). HUYA’s lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. For more information, please visit www.huyabio.com.